Y-mabs suffers 16-0 defeat at FDA vote

An FDA jury voted unanimously against recommending Y-mabs’ candidate omburtamab for the treatment of leptomeningeal metastasis from neuroblastoma indication.

Photo: Kelly Davidson Photography

The result of a vote at the FDA advisory committee on Y-mabs’ candidate omburtamab was clear:

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Bank believes in cancer approval for Genmab

In Jyske Bank’s eyes, Genmab’s newest cancer candidate is almost certain to be approved, though the bank says stock increases in the past year have reduced the upside potential for the Danish biotech firm.

Further reading

Related articles

Latest news

See all jobs